Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLC

PHASE2RecruitingINTERVENTIONAL

Enrollment

112

Participants

Timeline

Start Date

February 21, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

January 31, 2032

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

DRUG

Cemiplimab

Intravenously

DRUG

Platinum based chemotherapy

Intravenously

RADIATION

Stereotactic body radiation therapy

8 Gy times 3 treatment days (Days 1-3)

Trial Locations (1)

RECRUITING

Weill Cornell Medicine, New York

All Listed Sponsors

collaborator

Regeneron Pharmaceuticals

INDUSTRY

lead

Weill Medical College of Cornell University

OTHER

NCT06623656 - Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLC | Biotech Hunter | Biotech Hunter